Higher risk of type 2 diabetes in young women with polycystic ovary syndrome: A 10-year retrospective cohort study

Table 1 Baseline patient characteristics

	PCOS
	Yes (n = 2545)		No (n = 2545)		P value
	n	%	n	%
Age, yr					> 0.99
18-24	1497	58.8	1497	58.8
25-29	583	22.9	583	22.9
30-34	289	11.4	289	11.4
35-39	117	4.60	117	4.60
40-44	45	1.77	45	1.77
≥ 45	14	0.55	14	0.55
mean ± SD	25.1 ± 5.81		25.2 ± 5.91		0.63
Comorbidity
Disorders of lipid metabolism	38	1.49	38	1.49	> 0.99
Cardiovascular disease	3	0.12	8	0.31	0.13
Hypertension	27	1.06	27	1.06	> 0.99
Chronic kidney disease	2	0.08	4	0.16	0.41
Cerebrovascular accident	7	0.28	8	0.31	0.80
Infertility	151	5.93	151	5.93	> 0.99
Obesity	27	1.06	27	1.06	> 0.99
Hashimoto’s disease	5	0.20	4	0.16	0.74
Major depression	18	0.71	27	1.06	0.18
Anxiety	169	6.64	169	6.64	> 0.99
Medication (during follow-up period)
Metformin	238	9.35	18	0.71	< 0.0001
OCPs	443	17.4	72	2.83	< 0.0001
Clomiphene	1384	54.4	302	11.9	< 0.0001
Spironolactone	111	4.36	32	1.26	< 0.0001

Polycystic ovary syndrome group: follow-up time: 10.0; SD = 3.14. Control group: follow-up time: 10.0; SD = 3.16. PCOS: Polycystic ovary syndrome; OCPs: Oral contraceptive pills.